TRBV9 (Seniprutug Biosimilar) Recombinant Monoclonal Antibody

Code CSB-RA7153MB1HU
Size US$9799
Order now
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Target Names
TRBV9
Alternative Names
BCD180 research-grade biosimilar; BCD 180 research-grade biosimilar; BCD-180 research-grade biosimilar ;TRBV9 antibody; T cell receptor beta variable 9 antibody
Species Reactivity
Human
Immunogen
Recombinant Human TRBV9 protein
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated
Clonality
Monoclonal
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
0.01M PBS,pH7.4
Form
Liquid
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Notes
Validation Status
Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
Guaranteed Quality
① Antibody purity > 95% tested by SDS-PAGE.
② Endotoxin level < 0.1EU/ug tested by LAL method.
Lead Time
3-4 weeks
Description

This recombinant monoclonal antibody is designed as a research-grade biosimilar to Seniprutug, targeting TRBV9 (T-cell receptor beta variable 9), a specific variable region segment of the T-cell receptor beta chain. TRBV9 is one of the functional variable gene segments that contributes to TCR diversity through V(D)J recombination, enabling T cells to recognize a wide array of antigenic peptides presented by MHC molecules. The expression and clonal expansion of TRBV9-containing T cells have been implicated in various immune-mediated conditions and autoimmune diseases, where specific T-cell populations play pathogenic roles in disease progression.

Seniprutug represents an investigational therapeutic antibody developed to selectively deplete or modulate TRBV9-expressing T-cell populations. This biosimilar provides researchers with a valuable tool for investigating TRBV9-mediated immune responses, studying T-cell repertoire dynamics, and exploring therapeutic strategies targeting pathogenic T-cell clones in autoimmune and inflammatory disorders. The antibody enables detailed characterization of TRBV9+ T-cell subsets and their functional roles in immune homeostasis and disease pathology.

Usage
It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
V region of the variable domain of T cell receptor (TR) beta chain that participates in the antigen recognition. Alpha-beta T cell receptors are antigen specific receptors which are essential to the immune response and are present on the cell surface of T lymphocytes. Recognize peptide-major histocompatibility (MH) (pMH) complexes that are displayed by antigen presenting cells (APC), a prerequisite for efficient T cell adaptive immunity against pathogens. Binding of alpha-beta TR to pMH complex initiates TR-CD3 clustering on the cell surface and intracellular activation of LCK that phosphorylates the ITAM motifs of CD3G, CD3D, CD3E and CD247 enabling the recruitment of ZAP70. In turn ZAP70 phosphorylates LAT, which recruits numerous signaling molecules to form the LAT signalosome. The LAT signalosome propagates signal branching to three major signaling pathways, the calcium, the mitogen-activated protein kinase (MAPK) kinase and the nuclear factor NF-kappa-B (NF-kB) pathways, leading to the mobilization of transcription factors that are critical for gene expression and essential for T cell growth and differentiation. The T cell repertoire is generated in the thymus, by V-(D)-J rearrangement. This repertoire is then shaped by intrathymic selection events to generate a peripheral T cell pool of self-MH restricted, non-autoaggressive T cells. Post-thymic interaction of alpha-beta TR with the pMH complexes shapes TR structural and functional avidity.
Subcellular Location
Cell membrane.
Database Links

HGNC: 12246

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2026 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*